NASDAQ:LUMO Lumos Pharma (LUMO) Stock Price, News & Analysis → POTUS in ‘25 Not Biden/Trump, But (From The Freeport Society) (Ad) Free LUMO Stock Alerts $3.02 +0.21 (+7.47%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$2.73▼$3.0750-Day Range$2.45▼$3.0552-Week Range$2.41▼$4.55Volume270,583 shsAverage Volume13,217 shsMarket Capitalization$24.52 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lumos Pharma alerts: Email Address Lumos Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside496.0% Upside$18.00 Price TargetShort InterestBearish5.83% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$7,460 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.80) to ($2.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector531st out of 927 stocksPharmaceutical Preparations Industry230th out of 415 stocks 3.5 Analyst's Opinion Consensus RatingLumos Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLumos Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.83% of the float of Lumos Pharma has been sold short.Short Interest Ratio / Days to CoverLumos Pharma has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.Change versus previous monthShort interest in Lumos Pharma has recently decreased by 0.21%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLumos Pharma does not currently pay a dividend.Dividend GrowthLumos Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUMO. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lumos Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,460.00 in company stock.Percentage Held by Insiders25.40% of the stock of Lumos Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.99% of the stock of Lumos Pharma is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lumos Pharma are expected to grow in the coming year, from ($2.80) to ($2.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lumos Pharma is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lumos Pharma is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLumos Pharma has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Lumos Pharma Stock (NASDAQ:LUMO)Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.Read More LUMO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUMO Stock News HeadlinesApril 22, 2024 | americanbankingnews.comContrasting Ainos (NASDAQ:AIMD) and Lumos Pharma (NASDAQ:LUMO)April 18, 2024 | globenewswire.comLumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical MeetingsMay 2, 2024 | The Freeport Society (Ad)POTUS in ‘25 Not Biden/Trump, ButAnd I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.March 21, 2024 | markets.businessinsider.comLumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial OutcomesMarch 20, 2024 | globenewswire.comLumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042March 11, 2024 | sg.news.yahoo.comBAT set to sell stake in India's ITC stake as soon as this week, Bloomberg reportsMarch 10, 2024 | finance.yahoo.comLumos Pharma Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 9, 2024 | seekingalpha.comLumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call TranscriptMay 2, 2024 | The Freeport Society (Ad)POTUS in ‘25 Not Biden/Trump, ButAnd I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.March 8, 2024 | finanznachrichten.deLumos Pharma, Inc.: Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateMarch 8, 2024 | finance.yahoo.comLumos Pharma, Inc. (NASDAQ:LUMO) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | uk.finance.yahoo.comQ4 2023 Lumos Pharma Inc Earnings CallMarch 7, 2024 | investorplace.comLUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023March 7, 2024 | benzinga.comLumos Pharma: Q4 Earnings InsightsMarch 7, 2024 | globenewswire.comLumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development UpdateMarch 6, 2024 | benzinga.comEarnings Preview: Lumos PharmaMarch 6, 2024 | msn.comLumos Pharma FY 2023 Earnings PreviewFebruary 28, 2024 | finance.yahoo.comAxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of DirectorsFebruary 26, 2024 | globenewswire.comLumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024February 21, 2024 | msn.comExact Sciences (EXAS) Reports Q4 Loss, Tops Revenue EstimatesFebruary 5, 2024 | finance.yahoo.comLumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finance.yahoo.comLumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences ConferenceFebruary 5, 2024 | finance.yahoo.comIs Lumos Pharma (NASDAQ:LUMO) In A Good Position To Invest In Growth?January 4, 2024 | marketwatch.comLumos Pharma Elevates Pitukcheewanont to Medical ChiefJanuary 4, 2024 | msn.comLumos Pharma promotes Pisit Pitukcheewanont to chief medical officerDecember 22, 2023 | benzinga.comLumos Pharma Stock (NASDAQ:LUMO) Dividends: History, Yield and DatesDecember 8, 2023 | markets.businessinsider.comBullish Outlook: Buy Rating on Lumos Pharma on Promising LUM-201 Trials for Pediatric Growth DeficiencySee More Headlines Receive LUMO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lumos Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/01/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LUMO CUSIPN/A CIK1126234 Webwww.lumos-pharma.com Phone(512) 215-2630Fax515-296-3520Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$28.00 Low Stock Price Target$10.00 Potential Upside/Downside+496.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($4.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,030,000.00 Net Margins-1,659.39% Pretax Margin-1,660.80% Return on Equity-85.63% Return on Assets-65.30% Debt Debt-to-Equity RatioN/A Current Ratio5.69 Quick Ratio5.69 Sales & Book Value Annual Sales$2.05 million Price / Sales11.95 Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book0.88Miscellaneous Outstanding Shares8,116,000Free Float6,055,000Market Cap$24.51 million OptionableNot Optionable Beta0.65 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Richard J. Hawkins (Age 75)Founder, CEO & Chairman Comp: $854.35kDr. John C. McKew Ph.D. (Age 60)Chief Scientific Officer & President Comp: $860.38kLisa MillerSenior Director of Investor RelationsMr. Bradley J. Powers J.D. (Age 45)Chief Compliance Officer & General Counsel Comp: $677.08kMr. Aaron Schuchart B.B.A. (Age 58)CPA, M.B.A., Chief Business Officer Dr. Pisit Pitukcheewanont FAAPM.D., Chief Medical OfficerMr. Eddie L. Varnado M.B.A.Corporate ControllerMore ExecutivesKey CompetitorsBiora TherapeuticsNASDAQ:BIORCytoMed TherapeuticsNASDAQ:GDTCCumberland PharmaceuticalsNASDAQ:CPIXLisata TherapeuticsNASDAQ:LSTAOncternal TherapeuticsNASDAQ:ONCTView All CompetitorsInsiders & InstitutionsJohn C MckewSold 2,214 sharesTotal: $6,132.78 ($2.77/share)Blackstone Inc.Sold 141,593 shares on 2/15/2024Ownership: 4.128%John C MckewSold 438 sharesTotal: $1,327.14 ($3.03/share)Private Advisor Group LLCSold 4,000 shares on 2/6/2024Ownership: 0.202%John C MckewSold 3,407 sharesTotal: $10,936.47 ($3.21/share)View All Insider TransactionsView All Institutional Transactions LUMO Stock Analysis - Frequently Asked Questions Should I buy or sell Lumos Pharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lumos Pharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" LUMO shares. View LUMO analyst ratings or view top-rated stocks. What is Lumos Pharma's stock price target for 2024? 3 Wall Street analysts have issued 1-year target prices for Lumos Pharma's shares. Their LUMO share price targets range from $10.00 to $28.00. On average, they anticipate the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 496.0% from the stock's current price. View analysts price targets for LUMO or view top-rated stocks among Wall Street analysts. How have LUMO shares performed in 2024? Lumos Pharma's stock was trading at $3.18 at the beginning of the year. Since then, LUMO stock has decreased by 5.0% and is now trading at $3.02. View the best growth stocks for 2024 here. How were Lumos Pharma's earnings last quarter? Lumos Pharma, Inc. (NASDAQ:LUMO) posted its earnings results on Thursday, March, 7th. The company reported ($1.17) EPS for the quarter, beating analysts' consensus estimates of ($1.18) by $0.01. The company earned $0.83 million during the quarter, compared to analyst estimates of $0.01 million. Lumos Pharma had a negative net margin of 1,659.39% and a negative trailing twelve-month return on equity of 85.63%. During the same period last year, the company posted ($0.98) EPS. What other stocks do shareholders of Lumos Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lumos Pharma investors own include Advanced Micro Devices (AMD), Agilent Technologies (A), Air Lease (AL), Bionano Genomics (BNGO), Chimerix (CMRX), Compagnie de Saint-Gobain (CODYY) and How do I buy shares of Lumos Pharma? Shares of LUMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LUMO) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubYour bank is lying to you.MyBankTrackerDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lumos Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
